Avelox is a brand-name oral antibiotic that contains moxifloxacin as its active ingredient. It is supplied as a 400 mg pill and belongs to the fluoroquinolone class of antibiotics. In Hong Kong, Avelox is a prescription-only medication regulated by the Department of Health under the Medicines and Poisons Ordinance. The product is marketed by Bayer AG and is used to treat a range of bacterial infections when other agents are unsuitable.
Moxifloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are essential for DNA replication, transcription, and repair. By blocking them, moxifloxacin prevents bacterial cells from multiplying, leading to cell death. The drug is bactericidal and shows high activity against many Gram-positive, Gram-negative, and atypical respiratory pathogens. After oral administration, moxifloxacin is well-absorbed, reaching peak plasma concentrations within 1-2 hours, and has a half-life of approximately 12 hours, allowing once-daily dosing.
Avelox is approved in Hong Kong for the treatment of:
These indications are based on clinical trials demonstrating efficacy against the common causative bacteria for each condition.
Moxifloxacin has been investigated for several off-label indications, including:
These uses are not approved by the Hong Kong Department of Health and should only be considered under specialist supervision. Off-label use requires medical supervision and individualized risk assessment.
If any of these conditions apply, discuss alternatives with a healthcare professional.
If you are taking other medications, inform your prescriber to assess potential interactions.
Regular follow-up with your healthcare provider ensures optimal effectiveness and safety.
This article provides educational information about Avelox and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Combining antibiotics is sometimes done for polymicrobial infections, but it should only be pursued under medical supervision. Unsupervised combination may increase the risk of adverse effects or drug interactions.
Stop the medication immediately and seek medical evaluation. Early detection of tendon inflammation can prevent a full rupture, which may require surgical repair.
Avelox can prolong the QT interval. Patients with known QT prolongation, electrolyte disturbances, or on other QT-prolonging drugs should have cardiac monitoring and may need an alternative antibiotic.
Clinical improvement is often seen within 48-72 hours, though the full course of therapy should be completed as prescribed to ensure eradication of the infection.
Yes, but keep the medication in its original packaging with a copy of the prescription. Some countries may require documentation for import of prescription antibiotics.
Certain herbal products, such as St. John’s wort, can affect liver enzymes and alter drug levels. Inform your healthcare provider about all supplements you are taking.
Typical excipients include lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Patients with specific allergies should verify the full excipient list with the pharmacist.
Routine blood tests are not required for most patients, but baseline kidney and liver function tests may be ordered if you have underlying organ disease.
Fluoroquinolones have been associated with dysglycemia, especially in diabetic patients. Monitor blood glucose closely if you have diabetes while on Avelox.
Do not keep them for future use. Return unused tablets to a pharmacy or follow local disposal guidelines to prevent accidental ingestion.
